Research Papers:

The contribution of serum hepatitis B virus load in the carcinogenesis and prognosis of hepatocellular carcinoma: evidence from two meta-analyses

Xueqin Chen, Fan Wu, Yanmei Liu, Jiao Lou, Beibei Zhu, Li Zou, Wei Chen, Jing Gong, Ying Wang and Rong Zhong _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:49299-49309. https://doi.org/10.18632/oncotarget.10335

Metrics: PDF 1733 views  |   HTML 1862 views  |   ?  


Xueqin Chen1,2,*, Fan Wu3,*, Yanmei Liu4, Jiao Lou1, Beibei Zhu1, Li Zou1, Wei Chen1, Jing Gong1, Ying Wang5, Rong Zhong1

1Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

2Department of Medical Quality Management, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China

3Abdominal Surgery Department, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China

4Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

5Department of Virology, Wuhan Centers for Disease Prevention and Control, Wuhan, Hubei, China

*These authors contributed equally to this work

Correspondence to:

Rong Zhong, email: rongzhong91@gmail.com

Ying Wang, email: wangyingxiehe@163.com

Keywords: HBV DNA level, hepatocellular carcinoma, hepatocellular carcinoma recurrence, meta-analysis

Received: April 10, 2016     Accepted: June 13, 2016     Published: June 30, 2016


Background and Aim: The meta-analysis aimed to quantify and summarize the contribution of serum hepatitis B virus (HBV) DNA load in the carcinogenesis and prognosis of hepatocellular carcinoma (HCC).

Results: Nine independent studies with a total of 1162 cases and 9365 participants on risk of HCC and seventeen studies with 1342 cases and 2891 participants on recurrence of HCC were finally included. The non-liner dose-response association between HBV DNA level and HCC risk was observed, with P value equal to 0.02 for linear test. Compared with 2 log10copies/ml HBV DNA level carriers, the summary relative risk of HCC were 1.65(95% CI: 0.94–2.92) for 4.5 log10copies/ml, 2.20(95% CI: 1.00–4.85) for 5.5 log10copies/ml, 3.06(95% CI: 1.11–8.44) for 6.5 log10copies/ml. Moreover, individuals with high viral load (HBV DNA levels > 105copies/ml) presented significant association with increased risk of HCC recurrence, with the pooled RR of 1.69 (95% CI: 1.49–1.92).

Materials and Methods: Pertinent studies were identified by searching PubMed, Embase and ISI Web of science databases up to January 2016 and by reviewing the references of retrieved articles. The dose-response meta-analysis was precisely performed to calculate the summary relative risks (RRs) by quantizing the association between HBV load and risk of HCC. Besides, the contribution of HBV load on recurrence of HCC was further clarified by general meta-analysis.

Conclusions: These findings indicated a non-linear dose-response relationship between serum HBV DNA level and risk of HCC, and confirmed the significant contribution of serum HBV DNA level in the prognosis of HCC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10335